{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:15:16Z","timestamp":1768443316189,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"A Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan","award":["17K10913"],"award-info":[{"award-number":["17K10913"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00774-018-0928-x","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T10:41:12Z","timestamp":1525257672000},"page":"351-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol"],"prefix":"10.1007","volume":"37","author":[{"given":"Tsuyoshi","family":"Asano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimasa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"928_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. \n                    https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"928_CR2","unstructured":"(1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1\u20136"},{"key":"928_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401\u2013419. \n                    https:\/\/doi.org\/10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"key":"928_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161. \n                    https:\/\/doi.org\/10.1359\/jbmr.080901","journal-title":"J Bone Miner Res"},{"key":"928_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","volume":"25","author":"JP Brown","year":"2014","unstructured":"Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 25:1953\u20131961. \n                    https:\/\/doi.org\/10.1007\/s00198-014-2692-7","journal-title":"Osteoporos Int"},{"key":"928_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354. \n                    https:\/\/doi.org\/10.1016\/j.bone.2013.10.006","journal-title":"Bone"},{"key":"928_CR7","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","volume":"26","author":"S Ferrari","year":"2015","unstructured":"Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, Torring O, Kendler DL, Daizadeh NS, Wang A, O\u2019Malley CD, Wagman RB, Libanati C, Lewiecki EM (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26:2763\u20132771. \n                    https:\/\/doi.org\/10.1007\/s00198-015-3179-x","journal-title":"Osteoporos Int"},{"key":"928_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00198-016-3764-7","volume":"28","author":"M Kamimura","year":"2017","unstructured":"Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28:559\u2013566. \n                    https:\/\/doi.org\/10.1007\/s00198-016-3764-7","journal-title":"Osteoporos Int"},{"key":"928_CR9","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/boneres.2016.55","volume":"5","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Suzuki T, Kamimura M, Ikegami S, Murakami K, Uchiyama S, Taguchi A, Kato H (2017) Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res 5:16055. \n                    https:\/\/doi.org\/10.1038\/boneres.2016.55","journal-title":"Bone Res"},{"key":"928_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43:1243\u20131246. \n                    https:\/\/doi.org\/10.1111\/imj.12283","journal-title":"Intern Med J"},{"key":"928_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S0735-6757(12)00580-3","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31:e1\u2013e2. \n                    https:\/\/doi.org\/10.1016\/j.ajem.2012.11.011","journal-title":"Am J Emerg Med"},{"key":"928_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 8:295\u2013306. \n                    https:\/\/doi.org\/10.2147\/TCRM.S24239","journal-title":"Ther Clin Risk Manag"},{"key":"928_CR13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479. \n                    https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"},{"key":"928_CR14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831\u20131840. \n                    https:\/\/doi.org\/10.2147\/TCRM.S123172","journal-title":"Ther Clin Risk Manag"},{"key":"928_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2147\/TCRM.S142828","volume":"13","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Suzuki T, Kato H (2017) Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. Ther Clin Risk Manag 13:1343\u20131348. \n                    https:\/\/doi.org\/10.2147\/TCRM.S142828","journal-title":"Ther Clin Risk Manag"},{"key":"928_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49:605\u2013612. \n                    https:\/\/doi.org\/10.1016\/j.bone.2011.07.011","journal-title":"Bone"},{"key":"928_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-014-2993-x","volume":"26","author":"K Ebina","year":"2015","unstructured":"Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2015) Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda. Osteoporos Int 26:1445. \n                    https:\/\/doi.org\/10.1007\/s00198-014-2993-x","journal-title":"Osteoporos Int"},{"key":"928_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-018-0928-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:18:58Z","timestamp":1567073938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-018-0928-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s00774-018-0928-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tsuyoshi Asano, Tomohiro Shimizu, Daisuke Takahashi, Masahiko Takahata, Hiroki Hamano, Masahiro Ota, Shigeto Hiratsuka, Dai Sato, and Norimasa Iwasaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}